Oral Teriflunomide study recruiting relapsing MS patients

[MSUK]

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES).

Summary:Investigators in the United States and others around the world are recruiting 1455 people with relapsing multiple sclerosis for a study comparing two doses of oral teriflunomide(HMR1726), an investigational medication, or inactive placebo, in people taking any type of approved interferon beta. The study is sponsored by Sanofi-Aventis.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933

[HarryZ]

Rationale: Multiple sclerosis occurs when the immune system attacks the brain and spinal cord. Teriflunomide is a novel oral compound that inhibits the function of specific immune cells. Results from a two-year, phase III trial in 1,088 people with relapsing MS (the TEMSO trial), comparing two doses against placebo, showed that both doses significantly reduced the rate of MS relapses by up to 31.5% relative to placebo.

I guess this company has determined (nobody else has been able to prove this as yet) that MS occurs when the immune system attacks the brain and spinal cord.

And the efficacy is around 30% better than placebo. Now where have I seen these numbers before?

Harry